Size characterization of lipid-based self-emulsifying pharmaceutical excipients during lipolysis using Taylor dispersion analysis with fluorescence detection.

Self-emulsifying drug delivery systems based on lipids have gained in interest in recent years due to their capacity to enhance the bioavailability of poorly water soluble drugs. Their oral intake suggests that they will be in contact with gastric and pancreatic enzymes during their passage through the gastrointestinal tract. The study of the evolution of such systems in the presence of enzymes is thus essential to develop better drug delivery vehicles. In this work, the lipolysis of two lipid based self-emulsifying drug delivery systems, Labrasol® and Gelucire® 44/14 by pancreatic enzymes and under conditions mimicking the gastrointestinal tract are presented. The following of the digestion is realized by Taylor dispersion analysis using fluorescent detection. A hydrophobic marker was used to tag the microdroplets. Results have shown that, Labrasol® droplets decrease exponentially in size with lipolysis time, from 11.8 nm to 3.5 nm in 20 min. On the contrary, Gelucire® 44/14 droplets increased sigmoïdally in size from 5.6 to 24.7 nm. Even after 120 min lipolysis, both systems maintained a solubilizing capacity of the hydrophobic marker.

[1]  A. Müllertz,et al.  Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels , 2014, The AAPS Journal.

[2]  L. Cipelletti,et al.  Determination of individual diffusion coefficients in evolving binary mixtures by taylor dispersion analysis: application to the monitoring of polymer reaction. , 2010, Analytical chemistry.

[3]  M. Leser,et al.  Transitions in the internal structure of lipid droplets during fat digestion , 2011 .

[4]  C. Porter,et al.  In vitro assessment of oral lipid based formulations. , 2001, Advanced drug delivery reviews.

[5]  Ben J. Boyd,et al.  Inclusion of Digestible Surfactants in Solid SMEDDS Formulation Removes Lag Time and Influences the Formation of Structured Particles During Digestion , 2017, The AAPS Journal.

[6]  Dallas B. Warren,et al.  Real time evolution of liquid crystalline nanostructure during the digestion of formulation lipids using synchrotron small-angle X-ray scattering. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[7]  Sow-Hsin Chen,et al.  Characterization of colloidal structures during intestinal lipolysis using small-angle neutron scattering. , 2017, Journal of colloid and interface science.

[8]  S. Benita,et al.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  F. Carrière,et al.  In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol® and Gelucire® 44/14 , 2009, Pharmaceutical Research.

[10]  Christopher J. H. Porter,et al.  A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations , 2015, Pharmaceutical Research.

[11]  H. Cottet,et al.  Taylor dispersion analysis of mixtures. , 2007, Analytical chemistry.

[12]  F. Carrière,et al.  In Vitro Digestion of the Self-Emulsifying Lipid Excipient Labrasol® by Gastrointestinal Lipases and Influence of its Colloidal Structure on Lipolysis Rate , 2013, Pharmaceutical Research.

[13]  Anette Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. , 2014, Journal of pharmaceutical sciences.

[14]  C. Pouton,et al.  Enhancing intestinal drug solubilisation using lipid-based delivery systems. , 2008, Advanced drug delivery reviews.

[15]  A. Müllertz,et al.  Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations , 2013, Pharmaceutical Research.

[16]  Anette Müllertz,et al.  Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase , 2014, Pharmaceutical Research.

[17]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[18]  D. Hauss Oral lipid-based formulations. , 2007, Advanced drug delivery reviews.

[19]  F. Carrière,et al.  Understanding the lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. , 2012, Therapeutic delivery.

[20]  P. Righetti,et al.  Use of Taylor-Aris Dispersion for Measurement of a Solute Diffusion Coefficient in Thin Capillaries , 1994, Science.

[21]  H. Cottet,et al.  On the optimization of operating conditions for Taylor dispersion analysis of mixtures. , 2014, The Analyst.

[22]  Christopher J. H. Porter,et al.  years of oral lipid-based formulations : Provenance , progress and future perspectives ☆ , 2016 .

[23]  Jean-David Rodier,et al.  Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases. , 2008, Biochimica et biophysica acta.

[24]  H. Cottet,et al.  Size characterization of commercial micelles and microemulsions by Taylor dispersion analysis. , 2015, International journal of pharmaceutics.

[25]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. , 2012, Journal of pharmaceutical sciences.

[26]  D. Fatouros,et al.  Clinical studies with oral lipid based formulations of poorly soluble compounds , 2007, Therapeutics and clinical risk management.

[27]  Vincent Jannin,et al.  Hydrodynamic size characterization of a self-emulsifying lipid pharmaceutical excipient by Taylor dispersion analysis with fluorescent detection. , 2016, International journal of pharmaceutics.

[28]  J. Dressman,et al.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.

[29]  B. Bergenståhl,et al.  Morphological observations on a lipid-based drug delivery system during in vitro digestion. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  David J Brayden,et al.  Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. , 2016, Advanced drug delivery reviews.

[31]  M. Kuentz,et al.  In vitro digestion kinetics of excipients for lipid-based drug delivery and introduction of a relative lipolysis half life , 2012, Drug development and industrial pharmacy.

[32]  Christel A. S. Bergström,et al.  50years of oral lipid-based formulations: Provenance, progress and future perspectives. , 2016, Advanced drug delivery reviews.

[33]  B. Griffin,et al.  Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. , 2008, Advanced drug delivery reviews.

[34]  F. Carrière,et al.  Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain glycerides and PEG esters. , 2007, Biochimica et biophysica acta.

[35]  P. Constantinides,et al.  Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects , 1995, Pharmaceutical Research.

[36]  A. Joshi,et al.  Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead , 2015, Drug delivery.

[37]  Farooq Ali Khan,et al.  Nanoemulsion: Concepts, development and applications in drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[38]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. , 2012, Molecular pharmaceutics.